{"id":"dapsone-7-5-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Irritation at application site"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL1043","moleculeType":"Small molecule","molecularWeight":"248.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapsone works through dual mechanisms: it interferes with bacterial folate synthesis by inhibiting dihydropteroate synthase, making it bacteriostatic against susceptible organisms. Additionally, it possesses immunomodulatory and anti-inflammatory effects by suppressing neutrophil function and reducing the production of inflammatory cytokines, which is particularly beneficial in inflammatory skin conditions.","oneSentence":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and suppressing inflammatory mediators.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:03.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Rosacea"},{"name":"Dermatitis herpetiformis"}]},"trialDetails":[{"nctId":"NCT07244887","phase":"PHASE4","title":"Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris","status":"ENROLLING_BY_INVITATION","sponsor":"Oya Helin Dundar","startDate":"2025-06-17","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT03681470","phase":"PHASE4","title":"Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-04-09","conditions":"Acne Vulgaris","enrollment":20},{"nctId":"NCT05296460","phase":"PHASE4","title":"DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-09-01","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT04015375","phase":"PHASE3","title":"Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2019-07-11","conditions":"Acne Vulgaris","enrollment":1150},{"nctId":"NCT02959970","phase":"PHASE4","title":"Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2016-10-31","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT02944461","phase":"PHASE4","title":"Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2016-10","conditions":"Acne","enrollment":20},{"nctId":"NCT03132194","phase":"PHASE1","title":"Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-08-08","conditions":"Acne Vulgaris","enrollment":1125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aczone","topical dapsone 7.5% gel","Vulgarex (country-specific brand)"],"phase":"marketed","status":"active","brandName":"Dapsone 7.5 % gel","genericName":"Dapsone 7.5 % gel","companyName":"Derm Research, PLLC","companyId":"derm-research-pllc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapsone 7.5% gel is a small molecule inhibitor of dihydropteroate synthase 1, classified as an INHIBITOR. It is used to treat Acne Vulgaris, specifically in patients with skin of color, as indicated by clinical trials.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-07-07T00:00:00.000Z","mah":"ALMIRALL","brand_name_local":"ACZONE","application_number":"NDA021794"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-02-24T00:00:00.000Z","mah":"ALMIRALL","brand_name_local":"ACZONE","application_number":"NDA207154"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}